Tempus AI, Inc.

Tempus AI, Inc.

TEM · Nasdaq

Tempus AI, Inc. (TEM) is a Medical healthcare information services company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Tempus AI, Inc. in 2026. The next earnings report is expected on November 10, 2026.

Earnings calendar

Next earnings date

10 Nov 2026

In 83 days

EPS estimate

-0.11

Revenue estimate

413.5M

Past earnings

30 Jul 2026
EPS actual
-0.04 (+72.0%)
estimate -0.14
Revenue actual
382.5M (+0.7%)
estimate 379.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
05 May 2026
EPS actual
-0.13 (+34.9%)
estimate -0.20
Revenue actual
348.1M (+0.8%)
estimate 345.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
24 Feb 2026
EPS actual
-0.04 (-19.8%)
estimate -0.03
Revenue actual
367.2M (+1.2%)
estimate 362.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Tempus AI, Inc. beat consensus estimates in its latest earnings report, with EPS of $-0.04 versus an estimate of $-0.143 and revenue of $382.49 million exceeding estimates by 0.7%. Both EPS and revenue were also ahead of expectations in the previous report.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Sector
Healthcare
Industry
Medical healthcare information services
Country
United States
Exchange
Nasdaq
CEO
Eric Lefkofsky
Employees
2,400
IPO date
14 Jun 2024
ISIN
US88023B1035
Website
tempus.com

Frequently asked questions

When does Tempus AI, Inc. (TEM) next report earnings?

Tempus AI, Inc. (TEM) is scheduled to report earnings on November 10, 2026.

What was Tempus AI, Inc.'s most recent earnings date?

Tempus AI, Inc. (TEM) last reported earnings on July 30, 2026.

Where is Tempus AI, Inc. stock listed?

Tempus AI, Inc. (TEM) is listed on Nasdaq.